Non-interventional Study for Documentation of the Therapeutic Efficacy, Use and Tolerance of the Fixed-Dose Combinations (FDC) Duaklir® Genuair® (Aclidinium/Formoterol), Ultibro® Breezhaler® (Glycopyrronium/Indacaterol) and Anoro® (Umeclidinium/Vilanterol) in the Treatment of COPD Under Real Conditions in the Practices of Pneumologists, Internists, and General Practitioners
Non-interventional Study for Documentation of the Therapeutic Efficacy, Use and Tolerance of the Fixed-Dose Combinations (FDC) Duaklir® Genuair® (Aclidinium/Formoterol), Ultibro® Breezhaler® (Glycopyrronium/Indacaterol) and Anoro® (Umeclidinium/Vilanterol) in the Treatment of COPD Under Real Conditions in the Practices of Pneumologists, Internists, and General Practitioners
Prospective, multi-centre, non-interventional study to collect findings about the effects of LABA/LAMA (Long Acting Beta2-Agonists / Long Acting Muscarinic Antagonists) combination preparations on COPD (Chronic obstructive pulmonary disease) symptoms and quality of life under real conditions and to find out what types of patients are selected for this therapy by physicians.
Retrospective aspect of documentation: For patients who have already been changed over to a fixed-dose combination, lung function parameters and CAT (COPD Assessment Test™) score from the time prior to the changeover will be documented.
Inclusion Criteria:
Exclusion Criteria:
Aldenhofen, D6570r00001 D6570R00001, Germany
Euerbach-Obbach, D6570r00001 D6570R00001, Germany
Frankfurt/M., D6570r00001 D6570R00001, Germany
Koeln-Hoehenberg, D6570r00001 D6570R00001, Germany
Koeln-Rodenkirchen, D6570r00001 D6570R00001, Germany
Ludwigsburg-Ossweil, D6570r00001 D6570R00001, Germany
Neustadt/Aisch, D6570r00001 D6570R00001, Germany
Pulheim-Braunweiler, D6570r00001 D6570R00001, Germany